Abstract:Human serum has been intensively studied to identify biomarkers via global proteomic analysis. The altered O-glycoproteome is associated with human pathological state including cancer, inflammatory and degenerative diseases and is an attractive source of disease biomarkers. Because of the microheterogeneity and macroheterogeneity of O-glycosylation, site-specific O-glycosylation analysis in human serum is still challenging. Here, we developed a systematic strategy that combined multiple enzyme digestion, multidimensional separation for sample preparation and high-resolution tandem MS with Byonic software for intact O-glycopeptide characterization. We demonstrated that multiple enzyme digestion or multidimensional separation can make sample preparation more efficient and that EThcD is not only suitable for the identification of singly O-glycosylated peptides (50.3%) but also doubly (21.2%) and triply (28.5%) O-glycosylated peptides. Totally, with the strict scoring criteria, 499 non-redundant intact O-glycopeptides, 173 O-glycosylation sites and 6 types of O-glycans originating from 49 O-glycoprotein groups were identified in human serum, including 121 novel O-glycosylation sites. Currently, this is the largest data set of site-specific native O-glycoproteome from human serum samples. We expect that the strategies developed by this study will facilitate in-depth analyses of native O-glycoproteomes in human serum and provide opportunities to understand the functional roles of protein O-glycosylation in human health and diseases.BIOLOGICAL SIGNIFICANCE:The altered O-glycoproteome is associated with human pathological state and is an attractive source of disease biomarkers. However, site-specific O-glycosylation analysis is challenging because of the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of O-glycosylation. In this work, we developed a systematic strategy for intact O-glycopeptide characterization. This study took advantage of the inherent properties of the new fragmentation method called EThcD, which provides more complete fragmentation information about O-glycosylated peptides and a more confident site localization of O-glycans than collision-induced dissociation (HCD). We demonstrated that multiple enzyme digestion or multidimensional separation can make sample preparation more efficient and that EThcD was not only suitable for the identification of singly O-glycosylated peptides (50.3%) but also doubly (21.2%) and triply (28.5%) O-glycosylated peptides. Finally, we got a largest data set of site-specific native O-glycoproteome from human serum samples. Furthermore, quantitative analysis of intact O-glycopeptides from the serum samples of IgA nephropathy (IgAN) patients and healthy donors was performed, and the results showed the potential of the strategy to discover O-glycosylation biomarkers. We expect that the strategies developed by this study will facilitate in-depth analyses of native O-glycoproteomes in human serum and lead to exciting opportunities to understand the functional roles of protein O-glycosylation in human health and diseases.

Quantitative site-specific glycoproteomics by ZenoTOF reveals glyco-signatures for breast cancer diagnosis

Exploration of quantitative site-specific serum O-glycoproteomics with isobaric labeling for the discovery of putative O-glycoprotein biomarkers

High-Throughput Determination of the Site-Specific N.Sialoglycan Occupancy Rates by Differential Oxidation of Glycoproteins Followed with Quantitative Glycoproteomics Analysis

High-throughput site-specific N-glycoproteomics reveals glyco-signatures for liver disease diagnosis

Mass Spectrometry-Based N-glycoproteomics for Cancer Biomarker Discovery

Benchmark of site- and structure-specific quantitative tissue N-glycoproteomics for discovery of potential N-glycoprotein markers: a case study of pancreatic cancer

Proteomics Analysis of O-GalNAc Glycosylation in Human Serum by an Integrated Strategy

Robust Glycoproteomics Platform Reveals a Tetra‐Antennary Site‐Specific Glycan Capping with Sialyl‐Lewis Antigen for Early Detection of Gastric Cancer

Multiplexed surrogate analysis of glycotransferase activity in whole biospecimens

Pglycoquant with a Deep Residual Network for Precise and Minuscule-Missing-value Quantitative Glycoproteomics Enabling the Functional Exploration of Site-Specific Glycosylation

pGlycoQuant with a deep residual network for quantitative glycoproteomics at intact glycopeptide level

Systems Analysis of Singly and Multiply O-glycosylated Peptides in the Human Serum Glycoproteome Via EThcD and HCD Mass Spectrometry.

Comparative analysis of intact glycopeptides from mannose receptor among different breast cancer subtypes using mass spectrometry

Comparative Analysis of Site-Specific N-glycosylation of LAMP1 from Breast Cancer Tissues

Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers.

Tandem 18O Stable Isotope Labeling for Quantification of N-glycoproteome.

Comparative N-Glycoproteomics Analysis of Clinical Samples Via Different Mass Spectrometry Dissociation Methods

An Integrated Sample Pretreatment Platform for Quantitative N-glycoproteome Analysis with Combination of On-Line Glycopeptide Enrichment, Deglycosylation and Dimethyl Labeling.

A serum glycomics approach to breast cancer biomarkers

In-depth characterization and comparison of the N-glycosylated proteome of two-dimensional- and three-dimensional-cultured breast cancer cells and xenografted tumors

Discovery of Non-invasive Glycan Biomarkers for Detection and Surveillance of Gastric Cancer